Predictive Models for Designing Potent Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia for Understanding its Molecular Mechanism of Resistance by Molecular Docking and Dynamics Simulations

Multiple e-Pharmacophore modeling to identify a single molecule that could target both streptomycin and paromomycin binding sites for 30S ribosomal subunit inhibition

(2018) Anju C.P. et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors

(2017) Swapna Kamasani et al.   TUMOR BIOLOGY

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

(2017) Sandra Cuellar et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation

(2015) Jie Dong et al.   Journal of Cheminformatics

Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study

(2014) Hemanth Naick Banavath et al.   Scientific Reports

Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study

(2013) Karunakar Tanneeru et al.   PLoS One

Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing

(2010) Rohan Patil et al.   PLoS One